Editorial pubs.acs.org/chemneuro
Cite This: ACS Chem. Neurosci. 2018, 9, 1518−1519
New 2017 Data and Statistics for Pharmaceutical Products
Downloaded via 37.9.40.63 on August 9, 2018 at 02:37:57 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.
S
Table 1. 2017 Top 10 Global Prescription Drugs in Terms of Nonadjusted Sales5,6
tatistics for both global and regional pharmaceutical sales are now available, and once again strong growth was noted across every region as well as globally.1−3 In 2017, global pharmaceutical sales were $996 billion (almost $30 billion more than the $968 billion posted in 2016),1−3 with one source stating global drug spending at $1.135 trillion.4 By far, the United States remains the largest pharmaceutical market ($453 billion in 2017), followed by emerging markets ($216 billion in 2017, including China, Russia, Brazil, and India), Europe ($214 billion in 2017) and then established markets ($112 billion in 2017, including Japan, Canada, and Australia).5 Global sales are expected to exceed, for the first time, into the trillions of dollars in 2018, and by 2021, prescription drug spending in the United States alone is expected to reach $610 billion.1−5 For the United States, the $453 billion in 2017 sales is reduced to ∼$338 billion after all discounts and rebates are applied.1−5 Interestingly, using these adjusted values, data are available to view the Unites States market over time (Figure 1), and the growth in sales is staggering.6 As we have in the past,7,8 we will review trends, top drugs and other interesting caveats impacting the market.
rank
product
generic name
company AbbVie Roche/ Biogen Celgene Amgen/ Pfizer Roche BMS/Pfizer JNJ/Merck Roche Bayer/JNJ Bayer/ regeneron
1 2
Humira Rituxan
adalimumab MabThera
3 4
Revlimid Enbrel
lenalidomide etanercept
5 6 7 8 9 10
Herceptin Eliquis Remicade Avastin Xarleto Eylea
trastuzumab apixaban Infliximab bevacizumab Rivaroxaban Aflibercept
sales (US $BN)
% change vs 2016
18.427 9.238
+14.6 +2.0
8.187 7.885
+17.4 −11.1
7.441 7.395 7.152 7.096 6.589 6.034
+3.4 +46.3 −13.1 −1.4 +11.3 +9.4
terms of 2017 sales, Pfizer ($47.6 billion) was the leader among biotech and pharmaceutical companies (Table 2),9 while Johnson and Johnson (Table 3) nabbed the top spot in 2017 when considering net income ($16.3 billion).9 Table 2. 2017 Top 10 Biotech and Pharmaceutical Companies in Terms of Sales3
Figure 1. Adjusted prescription drug sales (drug expenditure) in the Unites States from 1960 ($2.7 billion) to 2017 ($338.1 billion).
The top 10 pharmaceutical product list changed from 2016,8 with the presence of more small molecule therapeutics to balance out the biologics.1−6,8 Moreover, the lists diverge slightly between based on source1−3,5,6 (Table 1), and I elected to present the data compiled by Statista.5,6 However, all sources agree that AbbVie’s Humira (adalimumab) hold the top spot with global sales of $18.4 billion (a 14.6% increase over 2016). Interestingly, biosimilars are waiting to launch, with Amgen’s Amjevita being the first to challenge in Humira in 2023.1−6,8 This will be key to watch, as Humira accounts for ∼70% of AbbVie’s sales income. The biggest mover in 2017 was Eliquis (apixiban), a direct factor Xa inhibitor anticoagulant, with an impressive 46.3 increase in sales. Revlimid moved from sixth position in 2016 to number 3 in 2017 with an impressive 17.4% increase.1−5,8,9 Whereas 9 of the top 10 in 2016 were biologics, 2017 witnessed only 7, and some notable traction in the small molecule space.1−5,8,9 In © 2018 American Chemical Society
rank
company
sales (US $BN)
1 2 3 4 5 6 7 8 9 10
Pfizer Novartis Roche Sanofi Johnson and Johnson Merck GlaxoSmithKline AbbVie Gilead Sciences Bayer
47.6 41.9 41.7 39.1 36.8 35.4 33.8 27.7 25.6 22.6
Table 3. 2017 Top 10 Biotech and Pharmaceutical Companies in Terms of Net Income9 rank
company
net income (US $BN)
1 2 3 4 5 6 7 8 9 10
Johnson and Johnson Gilead Science Roche Pfizer Amgen AbbVie Novartis Novo Nordisk Sanofi Merck
16.3 12.2 10 8.4 8.2 6.6 6.5 6.2 5.7 5.1
Published: July 18, 2018 1518
DOI: 10.1021/acschemneuro.8b00320 ACS Chem. Neurosci. 2018, 9, 1518−1519
ACS Chemical Neuroscience
Editorial
$1 trillion in global sales, for the first time. The list of top 10 global prescription drugs in 2017 saw major changes relative to 2016, and the percentage of biologics in the list decreased, i.e., small molecules gaining some traction. Looming patent expirations and biosimilars will likely have major impact on the rankings in 2018 and beyond. I hope the readership of ACS Chemical Neuroscience finds these data useful and thought provoking.
Express Scripts also just released their 2017 Drug Trend Report,10 and there were many interesting findings. In 2017, total per-person spending on prescription medications increased 1.5% for commercial drug plans, and inflammatory conditions was the top therapy class (and dominated by specialty brand drugs), followed by diabetes and oncology. For patients on medicare plans, total spending increased 2.3% per person and diabetes was the top therapy class, followed by oncology and inflammatory conditions. Finally, for patients on Medicaid plans, total spending increased 3.7% per person with HIV the dominant therapy class, followed by diabetes and inflammatory conditions.10 Across all plans, CNS therapy areas such as attention disorders, multiple sclerosis, depression, mental/neurological disorders, and pain were within the top 15 therapy classes. Finally, what were the most popular (most-filled) prescription drugs in 2017 and their average cost for a onemonth supply? These data were reported by GoodRx11 and are shown in Table 4. The top 10 are all exclusively small molecule
■
drug
avg cost (1 month supply)
1 2 3 4 5 6 7 8 9 10
lipitor synthroid prinivil vicodin norvasc prilosec ventolin flonase motrin steraped
$14 $11 $8 $14 $7 $11 $62 (one inhaler) $14 $13 $6
AUTHOR INFORMATION
ORCID
Craig W. Lindsley: 0000-0003-0168-1445 Notes
Views expressed in this editorial are those of the author and not necessarily the views of the ACS.
■
REFERENCES
(1) See https://www.genengnews.com/the-lists/the-top-15-bestselling-drugs-of-2017/77901068. (2) See http://www.businessinsider.com/common-popularprescription-drugs-us-2017-7. (3) Urquhart, L. (2018) Top drugs and companies by sales in 2017. Nat. Rev. Drug Discovery 17, 232. (4) See http://pharmaceuticalcommerce.com/business-and-finance/ global-drug-spending-was-1-135-trillion-in-2017-says-iqvia/. (5) See https://www.statista.com/statistics/272181/worldpharmaceutical-sales-by-region/. (6) See https://www.statista.com/statistics/184914/prescriptiondrug-expenditures-in-the-us-since-1960/. (7) Lindsley, C. W. (2016) 2015: A new impact factor for ACS Chemical Neuroscience and new topline data for global pharmaceutical products. ACS Chem. Neurosci. 7, 842−843. (8) Lindsley, C. W. (2017) New 2016 data and statistics for global pharmaceutical products and projections through. ACS Chem. Neurosci. 8, 1635−1636. (9) See https://www.statista.com/statistics/272720/top-globalbiotech-and-pharmaceutical-companies-based-on-net-income/. (10) See http://lab.express-scripts.com/lab/drug-trend-report/ 2017-dtr. (11) See https://www.goodrx.com/drug-guide.
Table 4. 2017 Top 10 Most Popular Prescription Medications and Costs for a One-Month Supply11 rank
Craig W. Lindsley, Editor-in-Chief
therapeutics, and the most popular was generic Lipitor, which long-held the number one spot in terms of annual drug sales prior to patent expiration. For a one-month supply, all costs were less than $20. On the other extreme, GoodRx also released statistics for the most expensive prescriptions ($ ∼31,000 to ∼$53,000 for a one-month supply) in the United States, and this list encompasses both biologics and small molecules (Table 5).11 Extrapolated for annual costs, these medications may cost upward of $400,000 to > $600,000/year before discounts and adjustments! 2017 was a tremendous year for the pharmaceutical industry in terms of product sales, approaching, and perhaps exceeding Table 5. 2017 Top 10 Most Expensive Prescription Medications and Costs for a One-Month Supply11 rank
drug
avg cost (1 month supply)
1 2 3 4 5 6 7 8 9 10
actimmune daraprim cinryze chenodal myalept H.P. Acthar juxtapid firazyr harvoni cuprimine
$53,321 $45,000 $44,140 $42,750 $42,137 $38,892 $36,992 $32,468 $31,500 $31,426 1519
DOI: 10.1021/acschemneuro.8b00320 ACS Chem. Neurosci. 2018, 9, 1518−1519
